3
Announcements
Trials
Browse
Landscape
Phase
Phase 1
1
Status
Withdrawn
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
CNS
1
Conditions
Keratosis, Actinic
3
Squamous Cell Carcinoma of Head and Neck
1
Prostatic Neoplasms
1
Pelvic Neoplasms
1
Pain
1
Oropharyngeal Neoplasms
1
Neoplasms, Cystic, Mucinous, and Serous
1
Glioblastoma
1
Colorectal Neoplasms
1
Carcinoma, Squamous Cell
1
Breast Neoplasms
1
Brain Neoplasms
1
Agnosia
1
Interventions
Temozolomide
38
Radiotherapy
22
Radiosurgery
22
Radiation
11
Magnetic Resonance Spectroscopy
11
Irinotecan
11
Cyclophosphamide
11
Etoposide
10
Surgical Procedures, Operative
9
Erlotinib Hydrochloride
9
Carmustine
9
pembrolizumab
8
Filgrastim
8
Carboplatin
8
Bevacizumab
7
Vincristine
6
Sorafenib
6
O(6)-benzylguanine
6
Nivolumab
6
Flucytosine
6
Aminolevulinic Acid
6
temsirolimus
5
sargramostim
5
Vorinostat
5
Trastuzumab
5
Topotecan
5
Lomustine
5
Imatinib Mesylate
5
Granulocyte Colony-Stimulating Factor
5
Everolimus
5
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Phase 1
×
Brain Neoplasms
×
Lidocaine
×
Clear all
NCT03177252
2020-10-22
Scalp block
Washington University School of Medicine
Phase 1
Withdrawn